PharmaCielo Ltd.
PCLOF
$0.06
$0.0114.73%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 121.59% | -8.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 121.59% | -8.31% |
| Cost of Revenue | -- | -- | -- | -6.97% | -31.06% |
| Gross Profit | -- | -- | -- | 151.43% | 102.78% |
| SG&A Expenses | -- | -- | -- | -35.89% | -40.38% |
| Depreciation & Amortization | -- | -- | -- | -38.28% | 149.75% |
| Other Operating Expenses | -- | -- | -- | -149.49% | 70.36% |
| Total Operating Expenses | -- | -- | -- | -30.13% | -32.58% |
| Operating Income | -- | -- | -- | 53.60% | 39.66% |
| Income Before Tax | -- | -- | -- | 44.53% | -8.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | 44.53% | -8.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | 44.53% | -8.51% |
| EBIT | -- | -- | -- | 53.60% | 39.66% |
| EBITDA | -- | -- | -- | 57.30% | 41.08% |
| EPS Basic | -- | -- | -- | 47.73% | -1.97% |
| Normalized Basic EPS | -- | -- | -- | 37.85% | 23.37% |
| EPS Diluted | -- | -- | -- | 47.73% | -1.97% |
| Normalized Diluted EPS | -- | -- | -- | 37.85% | 23.37% |
| Average Basic Shares Outstanding | -- | -- | -- | 6.84% | 6.51% |
| Average Diluted Shares Outstanding | -- | -- | -- | 6.84% | 6.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |